NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL lessened its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 59.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 87,353 shares of the medical research company's stock after selling 129,945 shares during the period. Tudor Investment Corp ET AL owned about 0.07% of NeoGenomics worth $1,440,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in NeoGenomics in the fourth quarter worth approximately $26,000. Versant Capital Management Inc raised its stake in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after buying an additional 1,142 shares in the last quarter. Sterling Capital Management LLC raised its stake in NeoGenomics by 788.7% in the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock worth $61,000 after buying an additional 3,289 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in NeoGenomics by 203.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after buying an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after buying an additional 1,103 shares in the last quarter. Institutional investors own 98.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on NEO. The Goldman Sachs Group cut their price target on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Benchmark lowered shares of NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Piper Sandler set a $12.00 price target on shares of NeoGenomics and gave the stock an "overweight" rating in a report on Tuesday, May 6th. Bank of America cut their price target on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. Finally, Leerink Partnrs lowered shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $13.83.

Insider Buying and Selling at NeoGenomics

In other news, CFO Jeffrey Scott Sherman acquired 20,000 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was acquired at an average price of $7.51 per share, for a total transaction of $150,200.00. Following the completion of the transaction, the chief financial officer now owns 158,494 shares in the company, valued at approximately $1,190,289.94. The trade was a 14.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen M. Kanovsky acquired 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $7.78 per share, with a total value of $31,120.00. Following the transaction, the director now owns 40,090 shares of the company's stock, valued at approximately $311,900.20. This trade represents a 11.08% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 59,900 shares of company stock valued at $463,532. 2.40% of the stock is owned by insiders.

NeoGenomics Stock Performance

Shares of NEO traded down $0.08 during trading hours on Friday, reaching $8.05. 961,071 shares of the company traded hands, compared to its average volume of 1,106,974. The stock has a market capitalization of $1.04 billion, a P/E ratio of -12.98 and a beta of 1.60. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 12-month low of $6.08 and a 12-month high of $19.12. The business has a fifty day moving average price of $9.21 and a 200-day moving average price of $13.08.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company had revenue of $168.04 million for the quarter, compared to analysts' expectations of $171.38 million. During the same period last year, the firm earned ($0.02) earnings per share. NeoGenomics's quarterly revenue was up 7.6% compared to the same quarter last year. Equities analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.